Funding for HUJ spinouts remained stable during the first six months of 2020 as the Israeli VC sector showed signs of resilience amid Covid-19.

Yissum, the tech transfer company for Hebrew University of Jerusalem, revealed yesterday that its spinouts had collectively generated $79m of funding over the first six months of 2020. The total includes tens of millions of dollars for 14 early-stage spinouts in segments such as cleantech, life sciences and artificial intelligence (AI). Yissum hailed the figures as further evidence of Israel’s startups bucking the trend of fewer venture dollars for their US and Europe-based counterparts amid the current economic climate. Israeli VC dollars climbed by an annual 40% year-on-year during the first six months of 2020, according to Forbes, while funding for the US and Europe was down by 10% and 20% respectively. Yissum spinouts to have raised funding during the reporting period included Tissue Dynamics, a drug development spinout that relies on AI and organ-on-a-chip technologies, and cancer immunotherapy company Nectin Therapeutics.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?